eFFECTOR Therapeutics Completes $38.6 Million Series C Financing

top of page

A L T I T U D E

Life Science Ventures

Widget Didn’t Load

Check your internet and refresh this page.

If that doesn’t work, contact us.

Featured Posts

Indigo Ag announces an additional $360M in financing, appoints Stéphane Bancel, Moderna CEO, to Boar

Sana Biotechnology Announces Completion of Initial Financing

Recent Posts

City Therapeutics Announces Strategic Collaboration with Bausch + Lomb to Develop a Novel RNAi-Based Treatment for Geographic Atrophy

Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC

Sana Biotechnology Announces Positive Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

U.S. Food and Drug Administration Accepts for Priority Review Nuvation Bio’s New Drug Application for Taletrectinib for the Treatment of Advanced ROS1-positive Non-Small Cell Lung Cancer

Tessera Therapeutics Receives Investment to Develop Curative In Vivo Genetic Treatment for Sickle Cell Disease

Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting

Tessera Therapeutics Highlights Advances Across In Vivo Programs for Sickle Cell Disease and T-Cell Therapies at the 66th American Society of Hematology Annual Meeting

Indigo Ag and Truterra launch strategic collaboration to accelerate adoption of agriculture sustainability solutions

Tessera Therapeutics Presents New Preclinical Data in In Vivo AATD and SCD Programs at the 31st Annual Congress of the European Society of Gene and Cell Therapy

Startup led by John Maraganore raises $135M to build ‘future of RNAi’

Archive

bottom of page